Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > GNMSF GENMAB AS > Detailed Quotes

GNMSF GENMAB AS

324.0000.0000.00%
Trading Session 09/29 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
324.000
Volume
0.00
Market Cap
21.33B
P/E(TTM)
38.33
52wk High
479.990
Shares
65.83M
P/E(Static)
46.53
52wk Low
260.250
Float Cap
21.12B
Bid/Ask %
0.00%
Historical High
500.920
Shs Float
65.17M
Volume Ratio
0.00
Historical Low
260.250
Dividend TTM
--
Div Yield TTM
--
P/B
6.69
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
Lot Size
1
Float Cap
21.12B
Bid/Ask %
0.00%
Historical High
500.920
Shs Float
65.17M
Volume Ratio
0.00
Historical Low
260.250
Dividend TTM
--
P/B
6.69
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
0.00%
Avg Price
Lot Size
1
Price Forecast

No Data

News

Comment

No More
Company Overview More
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
CEO: Dr. Jan G. J. van de Winkel, PhD
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...